Tuesday, July 17, 2018

HotSpot Therapeutics debuts with $45 million to pursue allosteric inhibitors

The company claims its technology will allow it to access previously undruggable targets

via Chemical & Engineering News: Biological SCENE https://ift.tt/2L4wauI

No comments:

Post a Comment